FDA-approved GLP-1s at their lowest prices. See if you qualify See all Weight Loss Lose weight with GLP-1s Learn about the Ro Body membership Tadalafil (Generic of Cialis) Megan Fox for Ro Sparks See all men's health Sperm Kit Member…
Rate Decision Day: How Is Zip Co (ASX:ZIP) Squaring Up? Software Bruises: Where Does Iress (ASX:IRE) Turn Next? Recruitment for XanaMIA closed earlier, and all patient visits are complete. The company confirmed in late October that the database…
In second-degree AV block some P waves reach the ventricles and some don't. In Mobitz I (Wenckebach) the PR interval lengthens beat by beat until a P wave fails to conduct; in Mobitz II the PR stays fixed and a…
The strongest benefit was seen in favorable-risk patients, who made up the majority of the 51 patients enrolled in the nationwide clinical trial, NCT01684397, conducted at five academic cancer centers. “This novel regimen of pazopanib alternating with bevacizumab was found to be…
The current disclosure centers on Announced that a global late-stage breast cancer study met its primary progression-free-survival endpoint. Attention now turns to clinical evidence and care delivery. This material is general market information and is not financial advice. It describes…
Wollongong-based online news outlet covering Australia and beyond. If you have anything newsworthy - a story, video or picture to share with us, please email us. Individuals' genetic background may affect ceramide metabolism to influence whether they benefit from androgen receptor…
ABP Live English Bharat Biotech's wholly owned subsidiary, Nucelion Therapeutics, has partnered with Hyderabad-based VeGen Bio to advance an experimental CAR-T cell therapy for multiple myeloma, a type of blood cancer The companies aim to bring the treatment, named VL-2511, to…
In 2026, midostaurin remains an established frontline FLT3 inhibitor for fit patients with FLT3-mutated AML and an approved KIT-directed therapy for advanced systemic mastocytosis, although newer, more selective FLT3 and KIT inhibitors have expanded treatment choices in both diseases. Its two major clinical…
Newswise — In a recent Yale-led clinical trial, a new type of prostate cancer drug showed promising results in reducing tumor activity and pain for patients with metastatic prostate cancer. “This is a first-in-class drug for prostate cancer,” says Daniel Petrylak,…
Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment. Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melano... Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European…
Trial design, systematic reviews, medical statistics, and guideline updates.
An article joins this feed when it matches these terms. Each one is also a search of its own.